Merck Sharp & Dohme's belzutifan (MK-6482), a treatment for the rare disorder von Hippel Lindau (VHL) disease, has become the first product to secure an “Innovation Passport” from the UK medicines agency, the MHRA, under a new regulatory pathway that kicked in on 1 January.
The Innovative Licensing and Access Pathway (ILAP) is intended to offer regulatory support and flexibilities to get novel products to patients more quickly, such as drugs for
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?